CXCL8 and colorectal carcinoma: Together with VEGF, which inhibitor is currently used as an antiangiogenic factor for the treatment of stage IV CRC, CXCL8 is also a potent promoter of angiogenesis that can promote vascularization at the tumor site, proliferation and metastasis of cancer cells and mediate recruitment of tumor infiltrating leukocytes [37–39].